Resultados da pesquisa - Patrick J. Roberts

  • A mostrar 1 - 18 resultados de 18
Refinar resultados
  1. 1
    PRESYNAPTIC γ‐AMINOBUTYRIC ACID RECEPTORS IN THE RAT ANOCOCCYGEUS MUSCLE AND THEIR ANTAGONISM BY 5‐AMINOVALERIC ACID

    PRESYNAPTIC γ‐AMINOBUTYRIC ACID RECEPTORS IN THE RAT ANOCOCCYGEUS MUSCLE AND THEIR ANTAGONISM BY 5‐AMINOVALERIC ACID Por M.Sherwan Muhyaddin, Patrick J. Roberts, G.N. Woodruff

    Publicado em 1982
    Obter o texto integral Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  2. 2
    Chemotherapy and CDK4/6 Inhibitors: Unexpected Bedfellows

    Chemotherapy and CDK4/6 Inhibitors: Unexpected Bedfellows Por Patrick J. Roberts, Vishnu Kumarasamy, Agnieszka K. Witkiewicz, Erik S. Knudsen

    Publicado em 2020
    Obter o texto integral
    Revisão
    Adic. favoritos
    Na minha lista:
  3. 3
    Preclinical Characterization of G1T28: A Novel CDK4/6 Inhibitor for Reduction of Chemotherapy-Induced Myelosuppression

    Preclinical Characterization of G1T28: A Novel CDK4/6 Inhibitor for Reduction of Chemotherapy-Induced Myelosuppression Por John E. Bisi, Jessica A. Sorrentino, Patrick J. Roberts, Francis X. Tavares, Jay C. Strum

    Publicado em 2016
    Obter o texto integral Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  4. 4
    Preclinical development of G1T38: A novel, potent and selective inhibitor of cyclin dependent kinases 4/6 for use as an oral antineoplastic in patients with CDK4/6 sensitive tumors

    Preclinical development of G1T38: A novel, potent and selective inhibitor of cyclin dependent kinases 4/6 for use as an oral antineoplastic in patients with CDK4/6 sensitive tumors Por John E. Bisi, Jessica A. Sorrentino, Jamie L. Jordan, David D. Darr, Patrick J. Roberts, Francis X. Tavares, Jay C. Strum

    Publicado em 2017
    Obter o texto integral Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  5. 5
    CDK4/6 inhibition induces epithelial cell cycle arrest and ameliorates acute kidney injury

    CDK4/6 inhibition induces epithelial cell cycle arrest and ameliorates acute kidney injury Por Derek P. DiRocco, John E. Bisi, Patrick J. Roberts, Jay C. Strum, Kwok‐Kin Wong, Norman E. Sharpless, Benjamin D. Humphreys

    Publicado em 2013
    Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  6. 6
    Rho Family GTPase Modification and Dependence on CAAX Motif-signaled Posttranslational Modification

    Rho Family GTPase Modification and Dependence on CAAX Motif-signaled Posttranslational Modification Por Patrick J. Roberts, Natalia Mitin, Patricia J. Keller, Emily J. Chenette, James P. Madigan, Rachel O. Currin, Adrienne D. Cox, Oswald Wilson, Paul T. Kirschmeier, Channing J. Der

    Publicado em 2008
    Obter o texto integral Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  7. 7
    CDK4/6 inhibition enhances antitumor efficacy of chemotherapy and immune checkpoint inhibitor combinations in preclinical models and enhances T-cell activation in patients with SCLC receiving chemotherapy

    CDK4/6 inhibition enhances antitumor efficacy of chemotherapy and immune checkpoint inhibitor combinations in preclinical models and enhances T-cell activation in patients with SCL... Por Anne Y. Lai, Jessica A. Sorrentino, Konstantin H. Dragnev, Jared Weiss, Taofeek K. Owonikoko, Julie Rytlewski, Jill Hood, Yang Zhao, Rajesh Malik, Jay C. Strum, Patrick J. Roberts

    Publicado em 2020
    Obter o texto integral Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  8. 8
    Multiple Roles of Cyclin-Dependent Kinase 4/6 Inhibitors in Cancer Therapy

    Multiple Roles of Cyclin-Dependent Kinase 4/6 Inhibitors in Cancer Therapy Por Patrick J. Roberts, John E. Bisi, Jay C. Strum, Austin J. Combest, David B. Darr, Jerry Usary, William C. Zamboni, Kwok‐Kin Wong, Charles M. Perou, Norman E. Sharpless

    Publicado em 2012
    Obter o texto integral Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  9. 9
    Transient CDK4/6 inhibition protects hematopoietic stem cells from chemotherapy-induced exhaustion

    Transient CDK4/6 inhibition protects hematopoietic stem cells from chemotherapy-induced exhaustion Por Shenghui He, Patrick J. Roberts, Jessica A. Sorrentino, John E. Bisi, Hannah Storrie-White, Renger G. Tiessen, Karenann M. Makhuli, William A. Wargin, Henko Tadema, Ewoud-Jan van Hoogdalem, Jay C. Strum, Rajesh Malik, Norman E. Sharpless

    Publicado em 2017
    Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  10. 10
    Combined PI3K/mTOR and MEK Inhibition Provides Broad Antitumor Activity in Faithful Murine Cancer Models

    Combined PI3K/mTOR and MEK Inhibition Provides Broad Antitumor Activity in Faithful Murine Cancer Models Por Patrick J. Roberts, Jerry Usary, David B. Darr, Patrick M. Dillon, Adam D. Pfefferle, Martin C. Whittle, James S. Duncan, Søren M. Johnson, Austin J. Combest, Jian Jin, William C. Zamboni, Gary L. Johnson, Charles M. Perou, Norman E. Sharpless

    Publicado em 2012
    Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  11. 11
    INX-315, a Selective CDK2 Inhibitor, Induces Cell Cycle Arrest and Senescence in Solid Tumors

    INX-315, a Selective CDK2 Inhibitor, Induces Cell Cycle Arrest and Senescence in Solid Tumors Por Catherine Dietrich, Alec Trub, Antonio Ahn, Michael Taylor, Krutika Ambani, Keefe T. Chan, Kun‐Hui Lu, Christabella A. Mahendra, Catherine Blyth, Rhiannon Coulson, Susanne Ramm, April C. Watt, Sunil Kumar Matsa, John E. Bisi, Jay C. Strum, Patrick J. Roberts, Shom Goel

    Publicado em 2023
    Obter o texto integral Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  12. 12
    Discrete vulnerability to pharmacological CDK2 inhibition is governed by heterogeneity of the cancer cell cycle

    Discrete vulnerability to pharmacological CDK2 inhibition is governed by heterogeneity of the cancer cell cycle Por Vishnu Kumarasamy, Jianxin Wang, Michelle Roti, Yin Wan, Adam P. Dommer, Hanna R. Rosenheck, Sivasankar Putta, Alec Trub, John E. Bisi, Jay C. Strum, Patrick J. Roberts, Seth M. Rubin, Costakis Frangou, Karen McLean, Agnieszka K. Witkiewicz, Erik S. Knudsen

    Publicado em 2025
    Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  13. 13
    Predicting Drug Responsiveness in Human Cancers Using Genetically Engineered Mice

    Predicting Drug Responsiveness in Human Cancers Using Genetically Engineered Mice Por Jerry Usary, Wei Zhao, David B. Darr, Patrick J. Roberts, Mei Liu, Lorraine Balletta, Olga Karginova, Jamie Jordan, Austin J. Combest, Arlene S. Bridges, Aleix Prat, Maggie C.U. Cheang, Jason I. Herschkowitz, Jeffrey M. Rosen, William C. Zamboni, Norman E. Sharpless, Charles M. Perou

    Publicado em 2013
    Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  14. 14
    Alterations of LKB1 and KRAS and risk of brain metastasis: Comprehensive characterization by mutation analysis, copy number, and gene expression in non-small-cell lung carcinoma

    Alterations of LKB1 and KRAS and risk of brain metastasis: Comprehensive characterization by mutation analysis, copy number, and gene expression in non-small-cell lung carcinoma Por Ni Zhao, Matthew D. Wilkerson, Usman Shah, Xiaoying Yin, Anyou Wang, Michele C. Hayward, Patrick J. Roberts, Carrie B. Lee, Alden M. Parsons, Leigh B. Thorne, Benjamin E. Haithcock, Juneko E. Grilley‐Olson, Thomas E. Stinchcombe, William K. Funkhouser, Kwok‐Kin Wong, Norman E. Sharpless, D. Neil Hayes

    Publicado em 2014
    Obter o texto integral Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  15. 15
    Lung Squamous Cell Carcinoma mRNA Expression Subtypes Are Reproducible, Clinically Important, and Correspond to Normal Cell Types

    Lung Squamous Cell Carcinoma mRNA Expression Subtypes Are Reproducible, Clinically Important, and Correspond to Normal Cell Types Por Matthew D. Wilkerson, Xiaoying Yin, Katherine A. Hoadley, Yufeng Liu, Michele C. Hayward, Christopher R. Cabanski, Kenneth L. Muldrew, C. Ryan Miller, Scott H. Randell, Mark A. Socinski, Alden M. Parsons, William K. Funkhouser, Carrie B. Lee, Patrick J. Roberts, Leigh B. Thorne, Philip S. Bernard, Charles M. Perou, D. Neil Hayes

    Publicado em 2010
    Obter o texto integral Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  16. 16
    Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ib/randomized phase II trial

    Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ib/randomized phase II trial Por J. Weiß, Tibor Csőszi, Marina Maglakelidze, Robert J. Hoyer, J.T. Beck, M. Dómine Gómez, Anna Łowczak, Raid Aljumaily, Caio M. Rocha Lima, Ralph V. Boccia, Wahid T. Hanna, Petros Nikolinakos, V.K. Chiu, Taofeek K. Owonikoko, Steven R. Schuster, Maen Hussein, Donald Richards, Piotr Sawrycki, Iurie Bulat, John Hamm, Lowell L. Hart, S. Adler, Joyce Antal, Anne Y. Lai, Jessica A. Sorrentino, Yang Zhao, Rajesh Malik, Shannon R. Morris, Patrick J. Roberts, K. Dragnev

    Publicado em 2019
    Obter o texto integral Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  17. 17
    A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response

    A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response Por Chen Zhao, Katherine A. Cheng, Zandra E. Walton, Yuchuan Wang, Hiromichi Ebi, Takeshi Shimamura, Yan Liu, Tanya Tupper, Jing Ouyang, Jie Li, Peng Gao, Michele Sue‐Ann Woo, Chunxiao Xu, Masahiko Yanagita, Abigail Altabef, Shumei Wang, Charles Lee, Yuji Nakada, Christopher G. Peña, Yanping Sun, Yoko Franchetti, Catherine Yao, Amy Saur, Michael D. Cameron, Mizuki Nishino, D. Neil Hayes, Matthew D. Wilkerson, Patrick J. Roberts, Carrie B. Lee, Nabeel Bardeesy, Mohit Butaney, Lucian R. Chirieac, Daniel B. Costa, David M. Jackman, Norman E. Sharpless, Diego H. Castrillón, George D. Demetri, Pasi A. Jänne, Pier Paolo Pandolfi, Lewis C. Cantley, Andrew L. Kung, Jeffrey A. Engelman, Kwok‐Kin Wong

    Publicado em 2012
    Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  18. 18
    CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation

    CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation Por Jiehui Deng, Eric S. Wang, Russell W. Jenkins, Shuai Li, Ruben Dries, Karen E. Yates, Sandeep Chhabra, Wei Huang, Hongye Liu, Amir Reza Aref, Elena Ivanova, Cloud P. Paweletz, Michaela Bowden, Chensheng W. Zhou, Grit S. Herter-Sprie, Jessica A. Sorrentino, John E. Bisi, Patrick H. Lizotte, Ashley A. Merlino, Max M. Quinn, Lauren E. Bufe, Annan Yang, Y. Zhang, Hua Zhang, Peng Gao, Ting Chen, Megan E. Cavanaugh, Amanda J. Rode, Eric Haines, Patrick J. Roberts, Jay C. Strum, William G. Richards, Jochen H. Lorch, Sareh Parangi, Viswanath Gunda, Genevieve M. Boland, Raphael Bueno, Sangeetha Palakurthi, Gordon J. Freeman, Jerome Ritz, W. Nicholas Haining, Norman E. Sharpless, Haribabu Arthanari, Geoffrey I. Shapiro, David A. Barbie, Nathanael S. Gray, Kwok‐Kin Wong

    Publicado em 2017
    Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:

Ferramentas de pesquisa: